Tuberculosis Clinical Trial
Official title:
Pattern Recognition of Volatile Organic Compounds (VOC) in Exhaled Breath for the Diagnosis of Pulmonary Tuberculosis
Verified date | November 2014 |
Source | Research Center Borstel |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Ethics Committee University of Luebeck |
Study type | Observational |
Tuberculosis is a bacterial infection causing 1.1 million deaths annually worldwide.
Diagnosis of the disease is often time consuming or challenging. Many cases of tuberculosis
require advanced and expensive diagnostic methods that restrict their availability in
resource limited countries where the burden of tuberculosis is highest. The development of
rapid point of care diagnostics is required.
Published data confirm that trained African giant-pouched rats are able to identify M.
tuberculosis cultures through olfactory recognition. A first trial using an electronic nose
reported a rate of detection of 85% in tuberculosis patients. A further trial was closed in
June 2011 but remains unpublished, yet. The olfactory pattern that potentially allows the
recognition of tuberculosis remains unknown.
This trial aims to detect first patterns of volatile organic compounds (VOCs) that bear a
potential for further development and fine tuning. A technical prototypic device of Siemens
is used for pattern detection.
The study is comparing 3 groups of patients:
- patients with confirmed active pulmonary tuberculosis (n=20)
- patients with other inflammatory lung diseases (pneumonia, sarcoidosis, COPD, bronchial
carcinoma) (n=20)
- healthy volunteers that do not work in the hospital or visit the hospital regularly
Detailed data for all study subjects will be collected for this trial in order to
eliminate confounding factors. Furthermore, detailed data of the surroundings of the
patient, the surroundings of the technical device and of the operator will be captured.
Hypothesis:
The pattern of exhaled volatile organic compounds allows the detection of pulmonary
tuberculosis
Status | Completed |
Enrollment | 60 |
Est. completion date | December 2013 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Confirmed pulmonary infection with M. tuberculosis (MTB) or other inflammatory disease of the lower respiratory tract (i.e. pneumonia, sarcoid, bronchial carcinoma) or healthy subject that is not employed or working at the study site 2. Oral and written consent to study participation Exclusion Criteria: 1. Tuberculosis therapy >1 week 2. Inability to follow the study requirements 3. Patient in custodianship or guardianship 4. Other lung diseases that are not listed in the inclusion criteria. |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Germany | Research Center Borstel | Borstel | Schleswig-Holstein |
Lead Sponsor | Collaborator |
---|---|
Research Center Borstel | Siemens Corporate Technologies |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of correctly identified patients with tuberculosis | The VOC pattern is used to differentiate tuberculosis patients from patients with non-tuberculosis inflammatory lung disease and from healthy volunteers | Day of admission to hospital | No |
Secondary | Change in VOC pattern induced by storage for several days | At days 3, 5 and 7 after sample collection | No | |
Secondary | Change in VOC pattern induced by storage temperature | At days 3, 5 and 7 after sample collection | No | |
Secondary | Change in VOC pattern induced by tuberculosis therapy | After completion of recruitment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |